Compare ADMA Biologics Inc (ADMA) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Dollar Tree, Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Dollar Tree, Inc. trades at $123.67 (market cap $23.57B). The key difference: Dollar Tree, Inc. is far larger — about 11.1× ADMA Biologics Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DLTR | |
|---|---|---|
Market Cap | $2.13B | $23.57B |
Sector | Health | Health |
52-Week High | $20.38 | $141.21 |
52-Week Low | $7.60 | $85.04 |
Enterprise Value | $2.20B | $30.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Dollar Tree (DLTR) trades at $122.65, down 1.13% on the day, but maintains a bullish technical signal with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights a new $2.5 billion share repurchase authorization, signaling management confidence. Revenue for 2025 was $17.58 billion, though net income was impacted by a significant tax expense, resulting in a loss. Analyst consensus is bullish with a $130.70 price target, and institutional sentiment is positive amid evolving value retail strategies.
The outlook for DLTR is cautiously optimistic, driven by earnings momentum, share buybacks, and margin improvements. Key opportunities include multi-price strategy gains and cost controls, but risks involve traffic softness, inflationary pressures, and competitive threats. The stock's current valuation metrics, such as a P/E of 19.5, appear reasonable relative to growth prospects, though investors should monitor execution against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
